JUNSHI BIO News

Junshi Biotech (688180): Tuoyi's sales revenue increased 57% year-on-year in Q1, and the expansion of indications achieved remarkable results

太平洋證券Apr 30 14:02

Junshi Biotech (688180): The performance of the core product, Tripley, exceeded expectations in Q1 in '24, performed brilliantly

方正證券Apr 29 00:00

Junshi Bio-U (688180): Treipril's indications for kidney cancer were approved to pioneer the first PD-1 monoclonal antibody immunotherapy for kidney cancer in China

方正證券Apr 8 20:16

Pacific released a research report on April 8 stating that it gave Junshi Biotech (688180.SH) a purchase rating. The main reasons for the rating include: 1) the company's product sales revenue increased dramatically in 2023, improving overall operating ef

Zhitong FinanceApr 8 17:44

Junshi Biotech (688180): Stable performance growth, PD-1 overseas commercialization can be expected

廣發證券Apr 6 00:00

Junshi Biotech (688180): The company's operational efficiency is steadily improving, and Tuoyi's overseas commercialization is progressing smoothly

太平洋證券Apr 2 00:00

Junshi Biotech (1877.HK): PD-1 monoclonal antibody approved by FDA and marketed at an accelerated pace

西南證券Mar 29 00:00

Junshi Bio-U (688180): The 23-year performance is in line with expectations, the future will continue to focus on innovation and the intensive harvest period is coming

方正證券Mar 29 00:00

Junshi Biotech (688180): The core pipeline continues to break through, and overseas commercialization of PD-1 can be expected

廣發證券Feb 28 07:26

Junshi Biotech - U (688180): Tripley's volume drives losses to narrow and the company's commercialization capacity continues to improve

方正證券Jan 31 16:11

Junshi Biotech (688180): Marginal improvement in performance, continued focus on product progress

東北證券Jan 30 00:00

Junshi Bio-U (688180): International first-class management team upgraded to comprehensively promote the company's domestic and overseas business progress

方正證券Jan 15 07:56

Junshi Biotech (688180): The company's general manager and CEO changed focus on performance catalysis

東北證券Jan 14 00:00

Junshi Bio-U (688180): The seventh indication of Trepri was launched to fully open up a new situation of perioperative treatment of lung cancer

方正證券Jan 4 07:32

Junshi Biotech (688180): Junshi's first domestic breakthrough in perioperative PD-1 indications

國金證券Jan 3 00:00

Junshi Biotech (688180) Review: Tuoyi was newly approved for NSCLC perioperative indications

東北證券Jan 2 00:00

Junshi Bio-U (688180): World-class teams join to help the company comprehensively improve Triplet and usher in a new starting point

方正證券Dec 15, 2023 00:00

Research Report Nuggets | Tianfeng Securities: Junshi Biotech Accelerates Late Pipeline R&D and Maintains “Buy” Rating

Gelonghui FinanceNov 20, 2023 13:30

Junshi Biotech (688180): Accelerate later pipeline development and strengthen the continuous development of core products

天風證券Nov 20, 2023 07:36

Junshi Biotech (688180): International breakthrough, clear PD-1 inflection point

浙商證券Nov 19, 2023 00:00